Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.43 |
| ▸ | CERT1 | Q9Y5P4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623032 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL9709528 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623366 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL679503 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL1623037 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL10958796 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5821483 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5185943 | 1.00 | MEN1 (0.54) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL557791 | 0.99 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 | |
| SCHEMBL5326495 | 0.99 | MEN1 (0.51) | MEN1KMT2ADEGS1FAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4323561-A | Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1982-04-06 | — | — | US | claimed |
| US-7928090-B2 | External preparation composition | LION CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7763595-B2 | Method of treatment of skin with external preparation composition | LION CORPORATION (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20100074856-A1 | EXTERNAL PREPARATION COMPOSITION | LION CORPORATION (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20090048211-A1 | EXTERNAL PREPARATION COMPOSITION | LION CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1941863-A2 | External preparation composition | Lion Corporation (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1917956-A2 | External preparation composition | Lion Corporation (JP) | 2008-05-07 | — | — | EP | disclosed |
| JP-2006008565-A | MICROCAPSULE INCLUDING GLUCOSAMINE FATTY ACID AMIDE COMPOUND AND COMPOSITION CONTAINING THE SAME | LION CORP | 2006-01-12 | — | — | JP | disclosed |
| US-20050239749-A1 | External preparation | LION CORPORATION (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1543821-A1 | EXTERNAL PREPARATION | Lion Corporation (JP) | 2005-06-22 | — | — | EP | disclosed |
| EP-0575517-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES, THE USE THEREOF AS VACCINES AND POLYVALENT HYPERIMMUNE GAMMAGLOBULINS | UNIVAX BIOLOGICS INCORPORATED (US) | 1993-12-29 | — | — | EP | disclosed |
| EP-0484403-A4 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES AND THE USE THEREOF AS VACCINES | — | 1993-03-17 | — | — | EP | disclosed |
| WO-1992016230-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES, THE USE THEREOF AS VACCINES AND POLYVALENT HYPERIMMUNE GAMMAGLOBULINS | UNIVAX BIOLOGICS INCORPORATED (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0484403-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES AND THE USE THEREOF AS VACCINES | UNIVAX BIOLOGICS INCORPORATED (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991001750-A1 | LIPID A ANALOG/IMMUNOGENIC CARRIER CONJUGATES AND THE USE THEREOF AS VACCINES | UNIVAX BIOLOGICS, INC. (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239749-A1 | External preparation | GLA, COLGALT1, GRN | MEN1 4506/4885KMT2A 3492/4885DEGS1 62/4885 |
| US-20100074856-A1 | EXTERNAL PREPARATION COMPOSITION | GLA, COLGALT1, DPM1 | MEN1 4542/4885KMT2A 3763/4885DEGS1 30/4885 |
| US-20090048211-A1 | EXTERNAL PREPARATION COMPOSITION | GLA, COLGALT1, DPM1 | MEN1 4542/4885KMT2A 3763/4885DEGS1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.